Eli Lilly acquired exclusive rights to a technology from Canada-based Entos Pharmaceuticals that the Indianapolis-based company believes will boost the development of nucleic acid therapeutics that target the central and peripheral nervous systems.
Biopharma companies Gennao Bio and Juno Diagnostics raised a combined $65 million in Series A funding rounds.
